{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.0","upperLimit":"64.0","value":"42.70"},{"groupId":"OG001","lowerLimit":"35.3","upperLimit":"47.9","value":"36.90"},{"groupId":"OG002","lowerLimit":"20.1","upperLimit":"32.7","value":"27.25"},{"groupId":"OG003","lowerLimit":"17.2","upperLimit":"64.2","value":"47.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"16"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"27.8","upperLimit":"40.3","value":"35.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"32.4","upperLimit":"48.1","value":"42.15"},{"groupId":"OG002","lowerLimit":"24.7","upperLimit":"36.4","value":"27.00"},{"groupId":"OG003","lowerLimit":"30.0","upperLimit":"79.9","value":"45.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"10"}],"units":"Participants"}],"title":"WEEK 5 DAY 1"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"27.8","upperLimit":"50.6","value":"36.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"WEEK 5 DAY 8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.1","upperLimit":"52.9","value":"41.80"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG001","lowerLimit":"44.4","upperLimit":"44.4","value":"NA"},{"groupId":"OG002","lowerLimit":"22.9","upperLimit":"46.6","value":"31.25"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG003","lowerLimit":"38.6","upperLimit":"52.1","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"2"}],"units":"Participants"}],"title":"WEEK 9 DAY 1"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"27.4","upperLimit":"56.8","value":"39.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"WEEK 9 DAY 8"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG000","lowerLimit":"28.1","upperLimit":"28.1","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG002","lowerLimit":"24.0","upperLimit":"36.3","value":"NA"},{"groupId":"OG003","lowerLimit":"39.5","upperLimit":"73.3","value":"50.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"WEEK 13 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG002","lowerLimit":"32.3","upperLimit":"44.8","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"WEEK 13 DAY 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"16"}],"units":"Participants"}],"description":"Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Full Range","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 1.9 milligram (mg)/kilogram (kg) dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide (Len) was administered as 25 mg or 10 mg per oral (PO) on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone (Dex) weekly PO/ intravenously (IV) on Days 1, 8, 15 and 22 of each cycle.","id":"OG000","title":"Main Study Phase: Belantamab Mafodotin 1.9mg/kg STRETCH + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG001","title":"Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG002","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG003","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 5 Day 1, Week 5 Day 8, Week 9 Day 1, Week 9 Day 8, Week 13 Day 1, Week 13 Day 8","title":"C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A","type":"SECONDARY","unitOfMeasure":"ug/mL"}